How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

What the FDA's new potency guidance means for rare disease gene therapy trials

calendar_today November 10, 2026 person Lisa Conroy, MPH domain sano

On November 2, 2026, the FDA issued its final guidance, Potency Assurance for Cellular and Gene Therapy Products , outlining a risk-based approach to ensuring that cell and gene therapies consistently achieve their intended biological activity. A Federal Register notice of availability followed.

open_in_new Read original post